How many drugs treat Intractable Eczema?

Drug Landscape tracks 2 marketed treatments for Intractable Eczema (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/intractable-eczema.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Intractable Eczema — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intractable Eczema (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Intractable Eczema, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Elidel	PIMECROLIMUS	Bausch Health	Calcineurin Inhibitor Immunosuppressant [EPC]	Peptidyl-prolyl cis-trans isomerase FKBP1A		2001-01-01
Prograf	TACROLIMUS	Astellas Pharma	Calcineurin Inhibitor Immunosuppressant	Interferon gamma		1994-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Astellas Pharma · 1 drug in Intractable Eczema
Bausch Health · 1 drug in Intractable Eczema

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Intractable Eczema:

Cite this brief

Drug Landscape (2026). Intractable Eczema — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/intractable-eczema. Accessed 2026-06-10.

Intractable Eczema full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing